Claims for Patent: 9,724,410

Summary for Patent: 9,724,410

Title:	Anti-IL-6 antibodies or fragments thereof to treat or inhibit cachexia, associated with chemotherapy toxicity
Abstract:	The present invention is directed to therapeutic methods and compositions, especially subcutaneous and intravenous composition using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient\'s survivability or quality of life will preferably be improved.
Inventor(s):	Smith; Jeffrey T. L. (Bellevue, WA), Latham; John A. (Seattle, WA), Litton; Mark (Seattle, WA), Schatzman; Randall (Redmond, WA)
Assignee:	ALDERBIO HOLDINGS LLC (Las Vegas, NV)
Application Number:	13/511,385
Patent Claims:	1. A method of treating or inhibiting cachexia in a patient exhibiting chemotherapy toxicity, comprising administering to the patient an anti-IL-6 antibody or an IL-6 binding antibody fragment comprising the variable light (V.sub.L) chain CDR1 of SEQ ID NO:4, CDR2 of SEQ ID NO:5 and CDR3 of SEQ ID NO:6, and the variable heavy (V.sub.H) chain CDR1 of SEQ ID NO:7, CDR2 of SEQ ID NO:8 or 120, and CDR3 of SEQ ID NO:9, wherein the patient's cachexia associated with the chemotherapy toxicity is effectively treated or inhibited. 2. The method of claim 1, wherein the anti-IL-6 antibody or IL-6 binding antibody fragment is aglycosylated and/or contains an Fc region that has been modified to alter effector function, half-life, proteolysis, and/or glycosylation. 3. The method of claim 1, wherein the anti-IL-6 antibody or IL-6 binding antibody fragment is human, humanized, single chain or chimeric. 4. The method of claim 1, wherein the anti-IL-6 antibody or IL-6 binding antibody fragment is administered to the patient with a frequency of about once every four weeks or eight weeks. 5. The method of claim 1, wherein said anti-IL-6 antibody or IL-6 binding antibody fragment comprises a human Fc derived from IgG1, IgG2, IgG3, or IgG4. 6. The method of claim 1, wherein the anti-IL-6 antibody or IL-6 binding antibody fragment has an elimination half-life of at least about 22 days, at least about 25 days or at least about 30 days. 7. The method of claim 1, wherein the anti-IL-6 antibody or IL-6 binding antibody fragment is coadministered with a chemotherapy. 8. The method of claim 1, wherein the patient has been diagnosed with an autoimmune disorder, infectious disorder or cancer. 9. The method of claim 1, wherein the anti-IL-6 antibody or IL-6 binding antibody fragment comprises a V.sub.H chain having at least 98% identity with the V.sub.H chain of SEQ ID NO:18 or 19, and a V.sub.L chain having at least 98% identity with the V.sub.L chain of SEQ ID NO:20. 10. The method of claim 1, wherein the anti-IL-6 antibody or IL-6 binding antibody fragment is administered intravenously or subcutaneously to the patient at a dose of about (+/-20%>) 80, 160 or 320 mg. 11. The method of claim 10, wherein the patient is administered said dosage every 8 weeks or 2 months. 12. The method of claim 10, wherein said dosage is administered at least twice. 13. The method of claim 10, wherein the second dose is administered 8 weeks after the first dose. 14. The method of claim 1, wherein the anti-IL-6 antibody or IL-6 binding antibody fragment comprises a V.sub.H chain having at least 95% identity with the V.sub.H chain of SEQ ID NO:18 or 19, and a V.sub.L chain having at least 95% identity with the V.sub.L chain of SEQ ID NO:20. 15. The method of claim 1, wherein the anti-IL-6 antibody or IL-6 binding antibody fragment comprises the V.sub.H chain of SEQ ID NO:18 or 19, and the V.sub.L chain of SEQ ID NO:20. 16. The method of claim 1, wherein the patient is administered a composition comprising the anti-IL-6 antibody or IL-6 binding antibody fragment, and wherein the composition is formulated for subcutaneous or intravenous injection. 17. The method of claim 1, wherein the patient has been diagnosed with cancer. 18. The method of claim 1, wherein the chemotherapy agent is selected from VEGF antagonists, EGFR antagonists, platins, taxols, irinotecan, 5-fluorouracil, gemcytabine, leucovorine, steroids, cyclophosphamide, melphalan, vinca alkaloids, vinblastine, mustines, tyrosine kinase inhibitors, radiotherapy, sex hormone antagonists, selective androgen receptor modulators, selective estrogen receptor modulators, PDGF antagonists, TNF antagonists, IL-1 antagonists, interleukins, IL-12R antagonists, Toxin conjugated monoclonal antibodies, tumor antigen specific monoclonal antibodies, Erbitux.TM., Avastin.TM., Pertuzumab, anti-CD20 antibodies, Rituxan.RTM., ocrelizumab, ofatumumab, DXL625, Herceptin.RTM., or any combination thereof. 19. The method of claim 1, wherein the chemotherapy cytotoxicity is caused by a chemotherapeutic agent comprising an inhibitor of JAK1, JAK2, JAK3, or SYK. 20. The method of claim 1, further comprising: measuring the patient's body weight prior to administration of the anti-IL-6 antibody or IL-6 binding antibody fragment, and administering the anti-IL-6 antibody or antibody fragment to the patient if the patient's weight has declined by greater than approximately 5% within approximately 30 days, or if the patient's lean body mass index is less than about 17 kg/m.sup.2 (male patient) or less than about 14 kg/m.sup.2 (female patient). 21. The method of claim 1, further comprising: measuring the patient's muscular strength prior to administration of the anti-IL-6 antibody or IL-6 binding antibody fragment, and administering the anti-IL-6 antibody or antibody fragment to the patient if the patient's muscular strength has declined by greater than approximately 20% within approximately 30 days. 22. The method of any one of claim 9, 14 or 15, wherein the anti-IL-6 antibody or IL-6 binding antibody fragment comprises the V.sub.H chain of SEQ ID NO:19. 23. The method of claim 1, wherein the V.sub.H chain CDR2 is SEQ ID NO:120. 24. The method of claim 1, wherein the anti-IL-6 antibody or IL-6 binding antibody fragment comprises the V.sub.H chain of SEQ ID NO:19 and the V.sub.L chain of SEQ ID NO:20 and human IgG1 constant domains. 25. The method of claim 1, wherein the anti-IL-6 antibody or IL-6 binding antibody fragment comprises the V.sub.H chain of SEQ ID NO:18 and the V.sub.L chain of SEQ ID NO:20 and human IgG1 constant domains.

Details for Patent 9,724,410

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	10/26/2009		2029-11-24
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	04/01/2011		2029-11-24
Novartis Pharmaceuticals Corporation	KESIMPTA	ofatumumab	Injection	125326	08/20/2020		2029-11-24
Genentech, Inc.	PERJETA	pertuzumab	Injection	125409	06/08/2012		2029-11-24
Genentech, Inc.	OCREVUS	ocrelizumab	Injection	761053	03/28/2017		2029-11-24